Stock Taper
SCREENER COMPARE ANY 2 STOCKS
EQ
EQUILLIUM, INC.
NASDAQ
$2.21
▼ DOWN 0.45% (-0.01)

KEY STATISTICS

Market Cap$140.68 M
52w High$3.54
52w Low$0.76
Dividend Yield—
Frequency—
P/E-6.91
Volume225.91K
Shares Out.63.23M

COMPANY

LEADERSHIP

Bruce D. Steel
CHIEF EXECUTIVE
Bruce D. Steel

COMPENSATION 2026

Salary$519,234
Stock Awards$0
Incentive Plan Pay$361,800
All Other Comp.$0
Total$4,255,248

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 12, 2018
METHOD OF GOING PUBLIC
SPAC
FULL TIME EMPLOYEES
14

PRICE TARGET

Target High$7.00
Target Low$5.00
Target Median$6.50
Target Consensus$6.25

UPCOMING EARNINGS

DateNov 12, 2026
DayThursday
Rev. Est.—
NOV
12
THU

PRICE

$2.21 ▼ DOWN 0.45% (−$0.01)
$2.21$2.22$2.24$2.259:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM2.21

About Equillium, Inc.

https://equilliumbio.com ↗

Equillium, Inc. is a clinical-stage biotech developing immuno-inflammatory therapies, including itolizumab (EQ001) for conditions like graft-versus-host disease, asthma, and lupus nephritis, based in La Jolla, California.

INDUSTRY

Biotechnology

A PRODUCT EQUILLIUM, INC. IS KNOWN FOR

EQ504
EQ504

EQ504 is Equillium's lead oral drug, a potent and selective AhR modulator in development for ulcerative colitis and other gastrointestinal and inflammatory lung diseases.

COMPETITORS

COMPETITOR
CUE COMPARE
HCWB COMPARE
KYTX COMPARE
ZBIO COMPARE

Revenue by Products

IconPRODUCTQ2-2024Q3-2024
Upfront Payment Amortization$1.3M $1M ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
16
LISTED HERE
5
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.4M
IWC
0.02% · 153.1K
AVSC
0.01% · 75.4K
QQQS
0.38% · 38.5K
DFMC
0.00% · 7.7K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
69.62%
HOLDERS
66
TOP 12 OF 66 · RANKED BY POSITION SIZE
Janus Henderson Group Plc
6.5M sh · $12.96M
Adar1 Capital Management, LLC
5.6M sh · $8.69M
Adage Capital Partners Gp, L.L.C.
5.3M sh · $10.66M
Decheng Capital Management Iii (Cayman), LLC
4.4M sh · $3.29M
Decheng Capital LLC
4.4M sh · $8.89M
Woodline Partners LP
3.5M sh · $5.02M
Abrdn Plc
3.4M sh · $6.71M
Ra Capital Management, L.P.
3.1M sh · $6.19M
Balyasny Asset Management L.P.
2.1M sh · $3.22M
Vanguard Group Inc
1.9M sh · $2.98M
Stempoint Capital LP
1.9M sh · $2.73M
Takeda Pharmaceutical Co Ltd
1.8M sh · $2.61M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book1
Overall Score2

INSIDER TRADES

★
OFFICER: PRESIDENT AND CSO
Connelly Stephen
Sale · 31.0K shares
2026-06-05
★
OFFICER: SR. VICE PRESIDENT AND COO
Zedelmayer Christine
Sale · 14.6K shares
2026-06-05
★
OFFICER: PRESIDENT AND CSO
Connelly Stephen
Sale · 200.0K shares
2026-06-04
★
OFFICER: SR. VICE PRESIDENT AND COO
Zedelmayer Christine
Purchase · 14.6K shares
2026-06-05

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
OUTPERFORM 1
2 GRADES IN THE LAST 12 MONTHS
Roth Capital BUY Leerink Partners OUTPERFORM

SECTORS PEERS

PEERPRICE
IPSC$2.14COMPARE
SPRB$57.54COMPARE
OTLK$0.68COMPARE
FBIO$2.71COMPARE
OSTX$1.89COMPARE
TELO$1.18COMPARE
CUE$27.46COMPARE
NRXP$3.42COMPARE